- Details
- Written by Amanda Turney
- Category: Latest News
Washington, DC - The U.S. Food and Drug Administration Wednesday approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy. Truxima is the first biosimiliar to be approved in the U.S. for the treatment of non-Hodgkin’s lymphoma.
- Details
- Written by IVP
- Category: Latest News
Orlando, Florida - Carol and Mark A. Atkinson, PhD, of Insulin for Life USA, are the recipients of the American Diabetes Association’s® (ADA’s) Humanitarian Award. This one-time award honors their outstanding leadership and humanitarian efforts to support the diabetes community for the Diabetes Emergency Relief Coalition in 2017. The Atkinsons were recognized with the award today at the ADA’s 78th Scientific Sessions, June 22-26, 2018, at the Orange County Convention Center in Orlando.
- Details
- Written by Michelle Kirkwood
- Category: Latest News
Orlando, Florida - A dual-hormone, artificial pancreas delivering rapid insulin and the drug pramlintide improved glucose control and reduced glucose variability in adults with type 1 diabetes (T1D) compared to an insulin-only, first-generation artificial pancreas, according to the study, “Insulin-plus-Pramlintide Artificial Pancreas in Type 1 Diabetes—Randomized Controlled Trial,” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center Convention Center.
- Details
- Written by Barbara McMakin
- Category: Latest News
Washington, DC - The Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT, a research program that helps streamline Phase II clinical trials for brain disorders, has been renewed for five more years, with several new centers joining the program. NeuroNEXT is supported by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.
- Details
- Written by Anne Trafton
- Category: Latest News
Cambridge, Massachusetts - In an advance that could lead to new treatments for a variety of diseases, MIT researchers have devised a new way to deliver messenger RNA (mRNA) into cells.
- Details
- Written by Sandy Walsh
- Category: Latest News
Washington, DC - The U.S. Food and Drug Administration approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first drug in its class (IDH1 inhibitors) and is approved for use with an FDA-approved companion diagnostic used to detect specific mutations in the IDH1 gene in patients with AML.
Page 1 of 18
- You are here:
-
Home
- Latest News